Hidradenitis Suppurativa

These findings resulted from a systematic literature review highlighting the impact of stigma and lack of support on self-image for patients with eczema, psoriasis, HS, and other conditions.

A study involving 6.2 million patients found smoking increases the risk of developing hidradenitis suppurativa, with quitting smoking significantly reducing this risk.

A phase 2 trial shows tofacitinib improves autoimmune conditions in Down syndrome, with notable skin health benefits and a good safety profile.

These data show that izokibep treatment of HS met each of its key primary and key secondary endpoints.

In this analysis, investigators highlighted the perceptions of individuals with HS and atopic dermatitis and assessed higher rates of stigmatization.

In this exclusive deep dive, a pair of leading dermatologists highlight the new data defining ruxotitinib cream, upadacitinib, and more agents from the revolutionary drug class.

Matthew Zirwas, MD, discusses the prospect of pairing JAK inhibitors like ruxolitinib cream with other disease-targeting options for conditions including vitiligo and alopecia areata.

Jennifer L. Hsiao, MD, reviews the rapidly growing inventory of investigational drugs for HS.

Matthew Zirwas, MD, explains why he believes agents like ruxolitinib cream and upadacitinib have become the optimal treatments for atopic dermatitis, hidradenitis suppurativa, and more.

Jennifer L. Hsiao, MD, discusses what the anticipated JAK inhibitors may provide to patients with HS if FDA-approved in the coming years.

Patients with hidradenitis suppurativa had the greatest risk of developing various CVS, with heart failure being the most common one.

The FDA announcement on bimekizumab’s supplemental Biologics License Application followed the phase 3 BE HEARD I and II studies’ conclusion.

Data show significant maternal and fetal risks in cases when pregnant women are diagnosed with hidradenitis suppurativa. A researcher discusses opportunities to learn more.

In this interview at AAD 2024, Porter discussed her team’s phase 2 findings on hidradenitis suppurativa the impact of ruxolitinib cream among those with Hurley Stage I and II.

Kimball discusses her team’s new late-breaking data regarding the safety and effectiveness of lutikizumab in treating the symptoms of moderate-to-severe HS in adult non-responders to anti-TNF therapy.

In this interview at AAD 2024, Porter discusses recent data from the SUNSHINE and SUNRISE trials on secukinumab for patients with HS.

These findings from AAD 2024 did not include statistically significant infliximab response predictors, though it had been the largest reported cohort on the subject to date.

A national cohort analysis presented at AAD 2024 showed a significant link between maternal HS exposure and poor health outcomes among children.

In this new analysis presented at AAD 2024, patients with HS saw substantial improvements in their hidradenitis suppurativa-related pain following treatment with bimekizumab.

New data presented at AAD 2024 highlights challenges in financial status, insurance and comorbidities among black pediatric patients with HS.

In this segment of Porter’s interview, she delves further into the phase 2 findings on lutikizumab and discusses any adverse events and future research.

In this interview, Porter describes some new and encouraging phase 2 data on lutikizumab treatment for patients with HS who had failed anti-TNF therapy.

The factors highlighted in this analysis may help dermatologists to better understand the concerns, misconceptions, and perceived risks reported by patients with HS.

The THESEUS study was conducted to look at current HS management and the influences on treatment decisions, with the goal of informing future randomized controlled trials.

In this analysis, the investigators note that the clinical association may be helpful to be taken into account as clinicians treat patients with HS.